Clinical Oncology Next-generation Sequencing Market is

Dubai, United Arab Emirates, January 27, 2022 (GLOBE NEWSWIRE) – Global Next generation sequencing market for clinical oncology It is valued at approx 449.4 million US dollars in 2022. With the increasing adoption of Next Generation Sequencing (NGS) in clinical oncology for personalized advanced treatment of cancer, the overall clinical oncology Next Generation Sequencing (NGS) market is expected to expand at a prolific CAGR 16.3% Between 2022 and 2029, up to a valuation in US dollars 1.14 Bn by 2029.

Next-generation sequencing refers to the identification of nucleotides of DNA base pairs for the diagnosis of various diseases. Oncology is an important application of next generation sequencing.

It is an advanced and faster method of sequencing. Next-generation sequencing in clinical oncology includes sequencing kits, reagents, services, platforms, and sequencing products. The kits and reagents used for sequencing are expected to experience significant growth in the overall clinical oncology next-generation sequencing market.

Describe details
Estimated Size of Next Generation Sequencing of Clinical Oncology Market in 2022 449.4 million US dollars
The forecast size of the next generation clinical oncology sequencing market in 2029 1.14 billion US dollars
Historic compound annual growth rate for the next generation clinical oncology market (2014-2021) 14.4%
Compound Annual Growth Rate (CAGR) Based on Next Generation Sequencing of Clinical Oncology Market Value (2022-2029) 16.3%

Request a sample report to get comprehensive insights into https://www.futuremarketinsights.com/reports/sample/rep-gb-9543

North America is expected to be a prominent region in the global next generation sequencing market in clinical oncology owing to the well-developed healthcare infrastructure and several technological developments in the region. North America and Europe are expected to witness a significant growth rate in the next generation sequencing market for clinical oncology.

Aggregate sequencing technology to retain a large market value share

Based on technology, the next-generation clinical oncology sequencing market has been segmented into pyro sequencing, sequencing by synthesis (SBS), single molecule real-time sequencing (SMRT), nanopore sequencing, splicing sequencing and reversible dye termination sequencing. However, assembly sequencing is expected to occupy a significant share in the next generation sequencing market for clinical oncology.

Ionic semiconductor sequencing is a method of DNA sequencing in which hydrogen ions are detected based on DNA polymerization. Thermal sequencing involves determining the arrangement of nucleotides in DNA based on the principle of “sequencing by synthesis”, where sequencing is carried out with the help of DNA polymerase. SBS is a technique used to identify the sequence of base pairs in DNA, also known as DNA sequencing.

For any inquiries related to the report, ask @analyst. https://www.futuremarketinsights.com/ask-question/rep-gb-9543

Report scope

Describe details
Historical data available for 2014-2021
prediction period 2022-2029
market analysis Units of volume and million dollars of value
Main areas covered North America, Latin America, Europe, East Asia, South Asia,
Oceania, Middle East and Africa
Main countries covered United States, Canada, Mexico, Brazil, Germany, United Kingdom, France,
Italy, Spain, Russia, Poland, China, Japan, South Korea,
India, ASEAN, Turkey, Saudi Arabia and South Africa
Main parts covered Component, technology, application, end user, and region
An overview of the main companies
  • Illumina, Inc.
  • F. Hoffmann-La Roche Ltd
  • Oxford Nanopore Technologies
  • Agilent Technologies
  • Thermo Fisher Scientific Inc., PerkinElmer, Inc.
  • Becton, Dickinson & Co
  • QIAGEN NV
  • Pacific Biosciences of California, Inc.
  • BGI . group
  • Takara Bio, you
  • Creative Biolabs
  • Mujin LC
Report coverage Market forecast, company share analysis, competition intelligence,
DROT analysis, market dynamics, challenges and strategic growth initiatives

There are many applications associated with the next generation clinical oncology market. They include whole tumor genome sequencing, whole tumor exome sequencing, target tumor genome profiling, tumor histology sequencing, comparisons of normal tumors, and other applications.

Targeted tumor genome classification is expected to capture a significant share of the next-generation clinical oncology treatment market. On the basis of the end user, the next generation clinical oncology sequencing market has been segmented into hospital laboratories, clinical research organizations, diagnostic laboratories, and others. Clinical research laboratories are expected to have a significant revenue share in the next generation sequencing market for clinical oncology.

We provide tailor-made solutions to suit your requirements, customization request @ https://www.futuremarketinsights.com/customization-available/rep-gb-9543

Apart from the factors driving the clinical oncology next-generation sequencing market, there are a few factors that are likely to hinder the overall growth of the clinical oncology next-generation sequencing market, such as high costs associated with setting up sequencing platforms, low quality outsourcing services, lack of Adequate availability of sequencing platforms in some regional markets.

On the other hand, increase in biomedical research using clinical oncology, increase in government funding for life science projects, significant reduction in sequencing prices, and technological advancement in the field of sequencing are some of the major factors driving the growth of clinical oncology next generation sequencing market.

Tier 1 companies own approximately 3/5y Share of global market value
The report tracks some of the key companies operating in the next generation clinical oncology sequencing market such as QIAGEN NV and Thermo Fisher Scientific. and Pacific Biosciences of California, Inc. and F. Hoffmann-La Roche Ltd Oxford Nanopore Technologies, Ltd. Takara Bio, Inc. is expected to own and Illumina Inc. and PerkinElmer Inc. and Agilent Technologies, Inc. Thermo Fischer Scientific and Oxford Nanopore Technologies Ltd. And Illumina has a significant share of the next generation clinical oncology sequencing market. These top-tier companies have an approximately 60% share in the next-generation sequencing market for clinical oncology.

Buy [email protected] https://www.futuremarketinsights.com/checkout/9543

Discover ongoing comprehensive coverage of FMI in healthcare

ECRP Devices Market – ERCP devices use a combination of fluoroscopy and luminal endoscopy to diagnose and treat disorders associated with the pancreaticobiliary system.

Confiscation Detectors Market – The Seizure Detectors Market study provides a comprehensive analysis of the business models, key strategies, and market shares of some of the most prominent players in this landscape.

Home Blood Testing Devices Market – A blood test is the primary diagnostic method used to identify abnormalities in human body systems. Regular blood tests are the easiest way to keep track of an individual’s health.

Vacuum Therapy Devices Market – Vacuum therapy devices are medical suction devices which are widely used in various types of vacuum treatments such as negative pressure wound treatment and also in erectile dysfunction disorders.

Bariatric Surgery Devices Market – Bariatric surgery has become relatively necessary for the majority of the world’s population, especially the obese and overweight populations. The fact that obesity is one of the most prevalent and endangered health disorders has led to increased awareness of bariatric surgery and devices.

Arthroscopy Devices Market – The arthroscopy devices market has emerged as one of the attractive industries in the medical equipment sector. In the recent past, the orthopedic industry has witnessed major private equity transactions, numerous mergers and innovative product launches acting as a major driver of the global arthroscopy devices market.

Orthotic devices Orthotic splints, orthopedic braces, and market supports – Orthotics can be defined as a support, brace or splint used to support, prevent, align or correct the functioning of movable body parts such as the neck, shoulder, wrist, knee, etc.

Lithotripsy Devices Market – Lithotripsy is a procedure that helps break the process of urolithiasis. Urolithiasis is the process of forming stones in the kidneys, bladder and/or urethra. Kidney stones are a common cause of blood in the urine and pain in the abdomen, flank or groin.

C-Arms Market – C-Arms is a medical imaging device based on X-ray technology that can be used flexibly. The name derives from the C-shaped arm used to connect the X-ray source and X-ray detector to each other.

Diabetes Care Devices Market – The global Diabetes Care Devices market is advancing at an average rate, registering a CAGR of 6.3% from 2022 to 2032.

About Future Market Insights (FMI)

Future Market Insights (FMI) is a leading provider of market information and advisory services, serving clients in more than 150 countries. FMI is headquartered in Dubai, with delivery hubs in the UK, US and India. The latest market research and industry analysis reports from FMI help companies face challenges and make critical decisions with confidence and clarity amidst intense competition. Our customized and syndicated market research reports provide actionable insights that drive sustainable growth. The expert-led team of analysts at FMI constantly track emerging trends and events in a wide range of industries to ensure our clients are prepared for the evolving needs of their clients.

Call:

future market insights,
1602-6 Jumeirah Bay Tower X2,
Part Number: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
The United Arab Emirates
For sales inquiries: [email protected]
For media inquiries: pr[email protected]
Website: https://www.futuremarketinsights.com/
Report: https://www.futuremarketinsights.com/reports/clinical-oncology-next-generation-sequencing-market
Press release source: https://www.futuremarketinsights.com/press-release/clinical-oncology-next-generation-sequencing-market

.

Leave a Comment